Belinda Yen-Lieberman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Belinda Yen-Lieberman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Colleen Starkey
Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
2 shared publicationsAaron P. Hoschar
Anatomic Pathology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio
1 shared publicationAlan J. Taege
Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH
1 shared publicationAnita Kroeger
Clinical Pathology, Cleveland Clinic, Cleveland, Ohio
1 shared publication- Benigno Rodriguez
The American British Cowdray Medical Center, Mexico City, Mexico
1 shared publication - Deborah J. Chute
Department of Pathology, Cleveland Clinic, Cleveland, USA
1 shared publication
Latest Publications
- 1 September 2017
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 89 (1) , 44-46
Preanalytic process linked to spuriously elevated HIV viral loads: improvement on an FDA-approved process
- 1 September 2017
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 89 (1) , 44-46
Preanalytic process linked to spuriously elevated HIV viral loads: improvement on an FDA-approved process
- 1 July 2014
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 3 (4) , 173-182
Hybrid Capture 2 human papilloma virus testing for head and neck cytology specimens
- 1 July 2014
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 3 (4) , 173-182
Hybrid Capture 2 human papilloma virus testing for head and neck cytology specimens
- Open Access
- 1 November 2005
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 12 (11) , 1298-1304
Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects
Tuberculosis (TB) is the most common life-threatening infection in human immunodeficiency virus (HIV)-infected persons and frequently occurs before the onset of severe immunodeficiency. Development of TB is associated with increased HIV type 1 (HIV-1) viral load, a fall in CD4 lymphocyte counts, and increased mortality. The aim of this study was to examine how treatment of pulmonary TB affected HIV-1 activity in HIV-1/TB-coinfected subjects with CD4 cell counts of >100 cells/μl. HIV-1/TB-coinfected subjects were recruited in Kampala, Uganda, and were monitored over time. Based upon a significant (0.5 log10copies/ml) decrease in viral load by the end of treatment, two patient groups could be distinguished. Responders (n= 17) had more rapid resolution of anemia and pulmonary lesions on chest radiography during TB treatment. This group had a significant increase in viral load to levels not different from those at baseline 6 months after completion of TB treatment. HIV-1 viral load in nonresponders (n= 10) with TB treatment increased and at the 6 month follow-up was significantly higher than that at the time of diagnosis of TB. Compared to baseline levels, serum markers of macrophage activation including soluble CD14 decreased significantly by the end of TB treatment in responders but not in nonresponders. These data further define the impact of pulmonary TB on HIV-1 disease. HIV-1 replication during dual HIV-1/TB infection is not amenable to virologic control by treatment of TB alone. Concurrent institution of highly active antiretroviral treatment needs to be evaluated in patients dually infected with pulmonary TB and HIV-1.
- 1 November 2005
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 12 (11) , 1298-1304
Open AccessPersistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects
Tuberculosis (TB) is the most common life-threatening infection in human immunodeficiency virus (HIV)-infected persons and frequently occurs before the onset of severe immunodeficiency. Development of TB is associated with increased HIV type 1 (HIV-1) viral load, a fall in CD4 lymphocyte counts, and increased mortality. The aim of this study was to examine how treatment of pulmonary TB affected HIV-1 activity in HIV-1/TB-coinfected subjects with CD4 cell counts of >100 cells/μl. HIV-1/TB-coinfected subjects were recruited in Kampala, Uganda, and were monitored over time. Based upon a significant (0.5 log10copies/ml) decrease in viral load by the end of treatment, two patient groups could be distinguished. Responders (n= 17) had more rapid resolution of anemia and pulmonary lesions on chest radiography during TB treatment. This group had a significant increase in viral load to levels not different from those at baseline 6 months after completion of TB treatment. HIV-1 viral load in nonresponders (n= 10) with TB treatment increased and at the 6 month follow-up was significantly higher than that at the time of diagnosis of TB. Compared to baseline levels, serum markers of macrophage activation including soluble CD14 decreased significantly by the end of TB treatment in responders but not in nonresponders. These data further define the impact of pulmonary TB on HIV-1 disease. HIV-1 replication during dual HIV-1/TB infection is not amenable to virologic control by treatment of TB alone. Concurrent institution of highly active antiretroviral treatment needs to be evaluated in patients dually infected with pulmonary TB and HIV-1.